Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease.

Published in: The Annals of pharmacotherapy (2024)

Daprodustat is a novel oral, non-iron therapy for treatment of anemia of CKD. It was Food and Drug Administration approved in 2023 in patients already receiving dialysis for at least 4 months but not in non-dialysis patients. Long-term data for safety and additional benefits are pending.

Keyphrases

chronic kidney disease
end stage renal disease
peritoneal dialysis
newly diagnosed
drug administration
prognostic factors
electronic health record
patient reported outcomes
deep learning
artificial intelligence